Funding Supports Ongoing Evaluation of AT2220 on ERT-Related Immunogenicity
CRANBURY, N.J., Feb. 7, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced the receipt of a two-year, $186,000 grant from the Muscular Dystrophy Association (MDA). The grant will be used to evaluate the effect of the pharmacological chaperone AT2220 (duvoglustat HCl) on immunogenicity related to the ERT alglucosidase alfa, the only approved treatment for Pompe disease.
Source: Amicus Therapeutics, Inc.
|
An eLearning module to learn about Pompe Disease, by going through the journey of Sam, recently diagnosed with Pompe Disease.